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To investigate long-term health sequelae of cryptosporidiosis, with especial reference to 20 
post-infectious irritable bowel syndrome (PI-IBS).  21 
Methods 22 
A prospective cohort study was carried out. All patients with laboratory-confirmed, 23 
genotyped cryptosporidiosis in Wales, UK, aged between 6 months and 45 years of age, 24 
over a two year period were contacted. 505 patients agreed to participate and were asked 25 
to complete questionnaires (paper or online) at baseline, 3 and 12 months after diagnosis. 26 
Presence/absence of IBS was established using the Rome III criteria for different age groups. 27 
Results 28 
205/505 cases completed questionnaires (40% response rate). At 12 months, over a third of 29 
cases reported persistent abdominal pain and diarrhea, 28% reported joint pain and 26% 30 
reported fatigue. At both 3 and 12 months, the proportion reporting fatigue and abdominal 31 
pain after C. hominis infection was statistically significantly greater than after C. parvum.  32 
Overall, 10% of cases had sufficient symptoms to meet IBS diagnostic criteria. A further 27% 33 
met all criteria except 6 months’ duration and another 23% had several features of IBS but 34 
did not fulfil strict Rome III criteria. There was no significant difference between C. parvum 35 
and C. hominis infection with regard to PI-IBS.  36 
Conclusions 37 
Post-infectious gastrointestinal dysfunction and fatigue were commonly reported 38 
after cryptosporidiosis. Fatigue and abdominal pain were significantly more common 39 
after C. hominis compared to C. parvum infection. Around 10% of people had 40 
symptoms meriting a formal diagnosis of IBS following cryptosporidiosis. Using age-41 
specific Rome III criteria, children as well as adults were shown to be affected. 42 
 43 
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Cryptosporidium is the commonest protozoal cause of acute gastroenteritis in the UK [1], 51 
with between 3,500 and 5,500 laboratory-confirmed cases reported annually in England and 52 
Wales from 2013 to 2015 [2]. The actual incidence of Cryptosporidium infection is almost 53 
certainly underestimated as asymptomatic carriage is possible [1] and diagnosis often 54 
requires a request for specific laboratory stool sample analysis. More than 90% of human 55 
cryptosporidiosis cases can be attributed to two species; Cryptosporidium parvum, a 56 
zoonotic species, and Cryptosporidium hominis, mainly adapted to humans [3]. 57 
Symptomatic cryptosporidiosis in immunocompetent patients is characterized by 58 
gastrointestinal symptoms that include sudden-onset, profuse, watery diarrhoea which may 59 
be accompanied by abdominal pain or cramps, vomiting and weight loss. Other, more non-60 
specific symptoms include malaise, fatigue, fever, nausea and muscle weakness [3]. The 61 
symptomatic period may last for up to 3 weeks, although the mean duration of symptoms 62 
has been reported as 12.7 days [1]. In over a third of cryptosporidiosis cases, relapse of 63 
diarrheal symptoms can occur within days of the initial symptomatic period resolving [4, 5, 64 
6]. In immunocompromised patients Cryptosporidium can produce severe symptoms which 65 
may persist to cause critical, sometimes life-threatening, illness [1]. Cryptosporidium 66 
infections in these patients may have an atypical presentation characterized by involvement 67 
of the liver, pancreas, gallbladder and, rarely, the respiratory system [7].  68 
Clearance of gastrointestinal pathogens, and the subsequent recovery of the 69 
gastrointestinal epithelium, usually coincides with the resolution of diarrheal symptoms, 70 
however, this is not always the case. Prospective and retrospective studies have shown that 71 
4-26% of patients can develop post-infectious irritable bowel syndrome (PI-IBS), following 72 
an initial acute gastroenteritis [8]. While the development of PI-IBS usually follows acute 73 
bacterial gastrointestinal infections, C. parvum in animal models can also induce 74 
pathophysiological features consistent with PI-IBS, such as jejunal hypersensitivity to 75 
distension and the accumulation of active mast cells, that is present 50 days after infection 76 
[9]. More recently, a study which followed up C. parvum outbreak cases found that 28% of 77 
cases still reported ‘IBS-like’ symptoms up to 12 months after the initial infection [10]. 78 
Relatively little is known about the longer-term health effects of Cryptosporidium infection. 79 
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However, there is growing evidence to suggest that, rather like some bacterial causes of 80 
gastroenteritis, Cryptosporidium infection may have longer-term consequences [4, 10, 11, 81 
12, 13].  82 
This is a prospective cohort study of laboratory-confirmed cryptosporidiosis cases in Wales 83 
sought to investigate the development of potential post-infection sequelae of both C. 84 
parvum and C. hominis over a 12-month time period, with particular attention to PI-IBS. 85 
 86 
Methods  87 
Data Collection: 88 
Cryptosporidium is a notifiable causative agent and all persons diagnosed with 89 
cryptosporidiosis in Wales are routinely contacted by an Environmental Health Officer 90 
(EHO). From July 2013 to July 2015, the EHO informed case patients, or their 91 
parents/guardians, that a study was in progress, and that our study team would contact 92 
them via post to seek to recruit them into the study. To be considered for recruitment into 93 
our study, participants had to be more than 6 months old, under 45 years old, and resident 94 
in Wales, with Cryptosporidium infection having been confirmed and genotyped from a 95 
faecal specimen by the national Cryptosporidium Reference Unit (CRU), Swansea within the 96 
two year study period. The submission of Cryptosporidium-positive stools by primary 97 
diagnostic laboratories to the CRU for genotyping is part of the routine diagnostic pathway. 98 
Any cases (or parents/guardians of a child case) who informed the EHO that they did not 99 
wish to take part in the research study were not considered as a potential study participant 100 
and were not contacted. The 45 year upper limit for age was used since patients over the 101 
age of 45 cannot be given a diagnosis of IBS without investigations to exclude other 102 
pathologies, according to the Rome III criteria. 103 
    104 
Those who consented to be contacted were sent an age-appropriate letter, information 105 
sheet and baseline questionnaire in either paper or internet-based format, depending on 106 
participant preference. The study questionnaire included questions aimed at establishing 107 
the presence or absence of symptoms of irritable bowel syndrome (IBS), as defined by the 108 
Rome III criteria for diagnosis of IBS [14]. The study questionnaires also enquired about 109 
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other symptoms related to potential post-cryptosporidiosis health sequelae previously 110 
reported in the literature.  111 
 112 
Questionnaires were specifically designed for three age groups; 6 months – 4 years, 5 – 17 113 
years and 18+ years. Different Rome III criteria for diagnosis of IBS apply to each of these 114 
age-groups. Study questionnaires were administered to each consenting 115 
participant/guardian on three occasions: baseline (as near to laboratory diagnosis of 116 
cryptosporidiosis as feasible); 3 months after diagnosis; and 12 months after diagnosis. In 117 
the baseline questionnaire, cases were asked about symptoms over the 6 months pre-dating 118 
their episode of cryptosporidiosis as well as their symptoms during their acute illness. 119 
 120 
Reminder letters were sent if there was no response within 2 weeks of a questionnaire 121 
being sent. If no response was received after 2 weeks, an additional questionnaire was sent. 122 
After this time, if there was no response, it was assumed that the person did not want to 123 
participate in the study, and no further contact was made by the study team. All returned 124 
paper questionnaires were quality checked and transferred into a central, secure electronic 125 
database, along with the online questionnaire data.  126 
 127 
Laboratory diagnosis 128 
Cryptosporidium was diagnosed in primary diagnostic laboratories using commercially-129 
available enzyme linked immunosorbent assays (ELISA) or auramine phenol or modified 130 
Ziehl-Neelsen stained microscopy.  131 
 132 
Genotyping 133 
Cryptosporidium-positive stools were genotyped at the CRU by real-time PCR incorporating 134 
C. parvum- and C. hominis-specific primers and probes based on the LIB13 and A135 genes 135 
respectively (15, 16). Other Cryptosporidium species were determined by sequencing part of 136 
the ssu rRNA gene (17). 137 
 138 
Data analysis 139 
Confidence intervals for proportions, risk ratios, 95% confidence intervals for risk ratios, chi 140 
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squared, and chi squared for trend were calculated used Stata 13 (StataCorp. 2013. Stata 141 
Statistical Software: Release 13. College Station, TX: StataCorp LP). 142 
Results 143 
Study Population 144 
From July 2013 to July 2015, 586 cases of Cryptosporidium were notified in Wales, of which 145 
515 were confirmed at the Reference Unit, genotyped and reported to our study team. 52%  146 
were < 18 years old. The predominant infecting species was C. parvum (n=300), followed by 147 
C. hominis (n=200), C. cuniculus (n=9), C. felis (n=3), both C. hominis and C. parvum (n=2) 148 
and C. ubiquitum (n=1). Infecting species by age group is shown in Table 1. 505 of these 149 
cases agreed to be contacted about the study and were sent questionnaires. 150 
 151 
205 case patients completed study questionnaires, a 40% response rate. Complete data sets 152 
for analysing sequelae (baseline, 3 months and 12 months questionnaires) were obtained 153 
from 89 participants, while partial data sets were obtained from a further 43 participants 154 
(Table 2). A further 73 participants were ineligible for inclusion in the analysis of sequelae as 155 
no follow-up questionnaires were completed after baseline. However, they were included in 156 
the analysis of the presenting symptoms of acute cryptosporidiosis. 157 
 158 
Overall, the proportion of female to male participants was higher throughout the duration 159 
of this study: 60.6% female at baseline, 58.2% female at 3 months and 66.3% female at 12 160 
months. A higher proportion of females was represented amongst the participants than 161 
among the 515 eligible case patients who were initially contacted, of whom 274 (53%) were 162 
female. In terms of age, there were 42 respondents from 113 cases age 6 months-4 years 163 
(response rate 37%), 63 respondents from 156 cases age 5-17 years (response rate 40%) and 164 
100 respondents from 246 cases aged over 18 (response rate 41%). Therefore there was 165 
little difference in response rates between the different age groups. At all time-points, the 166 
18+ years age group accounted for approximately half of all the responses received (50.8% 167 
at baseline, 46.4% at 3 months, 50.6% at 12 months), with 5-17 years being the next most 168 
represented age group and 6 months - 4 years being the least represented. The proportion 169 
of under-18s participating was similar to the proportion of eligible cases contacted (52%). 170 
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Female participants were significantly older than male participants, chi squared for trend 171 
p<0.001 (Figure 1). 172 
 173 
Acute Symptoms 174 
All cases reported diarrhea. The proportions of cases reporting other symptoms are shown in Table 175 
3. Abdominal pain, anorexia, nausea, fatigue, weight loss and fever were each seen in over half of all 176 
cases. Joint pain was reported in over a quarter. Table 3 also shows the acute symptoms analysed by 177 
those reported with C. hominis and with C. parvum. The only symptom for which a statistically 178 
significant difference in incidence was found between the species was eye pain, which was 179 
commoner with C. hominis (p=0.03).  180 
Table 4 shows the acute symptoms broken down by age-group. Vomiting was reported by over half 181 
of under-18s but only by just over a third of adults, and occurred more frequently in children 182 
(p=0.01), an observation which is consistent with our anecdotal clinical experience. Fatigue was 183 
more commonly reported in adults, over three-quarters vs just over half (p=0.01). Joint pains, 184 
headache, dizzy spells, eye pain and blurred vision may be difficult to identify in young children 185 
which may explain why they were infrequently reported in the under-5s in this study. 186 
3 month and 12 month sequelae 187 
Symptoms reported at 3 months and/or 12 months were only recorded if they were 188 
reported as having been absent prior to the acute illness. Symptoms reported at 3 months 189 
and 12 months which were not reported as present prior to the acute illness are shown in 190 
Table 5. At 3 months, 43% of cases reported abdominal pain and 40% reported fatigue. 191 
Diarrhoea was still reported by 36% and 32% reported loss of appetite. At 12 months, 192 
abdominal pain and diarrhea were still being reported in over a third of cases overall. The 193 
other most commonly reported symptoms at 12 months which were not present prior to 194 
infection were joint pain (28%) and fatigue (26%). 195 
When comparing cases who had C. hominis with those who had C. parvum, at 3 months (Table 6), 196 
symptoms tended to be more frequent with C. hominis. The numbers reporting fatigue (p=0.003), 197 
vomiting (p=0.04) and abdominal pain (p=0.045) after C. hominis infection were all statistically 198 
significantly greater. 199 
At 12 months (Table 7), a comparison of symptoms reported after C. hominis with C. parvum again 200 
found a statistically significant higher reported incidence of fatigue (p=0.002) and abdominal pain 201 
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(p=0.04) associated with C. hominis.  The difference in reported incidence of vomiting was no longer 202 
marked at 12 months (p=0.76). 203 
IBS 204 
Prior to this part of the analysis, nine participants were excluded: seven of these already had 205 
a doctor’s diagnosis of IBS prior to the acute cryptosporidiosis, the other two met the Rome 206 
III criteria at baseline. All excluded participants belonged to the 18+ age group. None of the 207 
participants who already had a diagnosis or evidence of IBS at baseline reported that their 208 
pre-existing IBS worsened in the 12 months following their Cryptosporidium infection. 209 
For identifying IBS the Rome III diagnostic criteria were used. Overall, 10% of cases had 210 
features diagnostic for IBS. No significant difference was seen between C. parvum and C. 211 
hominis with regard to IBS (Table 8). The distribution by age group is shown in Figure 2. 212 
Discussion 213 
A small number of previous studies have investigated post-acute symptoms after 214 
cryptosporidiosis [4, 10, 11, 12, 13]; however, most did not include both C. hominis and C. 215 
parvum infections, and some did not have a follow-up period of sufficient duration to be 216 
able to identify PI-IBS, a diagnosis of which requires symptoms to have been present for at 217 
least 6 months [14]. Anecdotally, Cryptosporidium infection has also been associated with 218 
the development of reactive arthritis [18, 19, 20], Reiter's syndrome [21], acute pancreatitis 219 
[22, 23] and haemolytic uraemic syndrome [24].  220 
 221 
Hunter et al. [4], found that loss of appetite, vomiting, abdominal pain and diarrhoea were 222 
more commonly reported in both C. hominis and C. parvum cases than in non-cases after a 2 223 
month follow-up period, while joint pain, fatigue, dizzy spells, recurrent headache and eye 224 
pain were more commonly reported by those with C. hominis infections. Among presenting 225 
complaints during acute illness with C. parvum and C. hominis, our study also found an 226 
increased proportion of cases reporting eye pain during acute C. hominis infection 227 
compared with C. parvum (p=0.03), and identified that vomiting is more common in children 228 
than in adults in acute cryptosporidiosis. Similarly, another study of C. hominis and C. 229 
parvum cases found that dizziness, fatigue, weight loss, diarrhea and abdominal pain were 230 
commonly reported up to 4 months post-infection, but did not identify any difference in 231 
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sequelae between the two species [13]. In contrast, here, fatigue and abdominal pain was 232 
reported at both 3 months and 12 months significantly more often after C. hominis than C. 233 
parvum. Vomiting was also seen more commonly at 3 months after C. hominis infection but 234 
this difference was no longer apparent at 12 months. Intermittent diarrhoea, persistent 235 
abdominal pain, myalgia/arthralgia and fatigue, have been reported up to 3 years post-236 
Cryptosporidium infection [12]. A study of C. hominis outbreak cases found a significant 237 
incidence of fatigue, nausea and joint pain in cases, when compared to non-cases, up to 11 238 
months post-infection [11]; and even persisting up to 28 months later [25]. A 2017 study of 239 
a C. parvum outbreak [10] found that abdominal pain, diarrhoea, joint pain, weight loss, 240 
fatigue and eye pain were still being reported up to 12 months post-infection.  241 
 242 
A formal diagnosis of IBS requires that symptoms have been present over a period of time 243 
greater than 6 months. Cases reporting all features required for an IBS diagnosis were 244 
categorised as IBS RIII. At the time of the 3 month questionnaire, it was not possible for 245 
participants to report new symptoms diagnostic of IBS that had been present for more than 246 
6 months. Therefore cases who at 3 month follow-up reported all features of IBS except 247 
duration >6 months were categorised as ‘IBS RIII <6m’. In some cases enough information 248 
was given to identify a functional change in bowel habit consistent with IBS, but the 249 
information given was not specific enough to assign them with certainty to the IBS group. 250 
The problematic criteria in these instances were: how often they had pain – the Rome III 251 
criteria specify 3 times per month minimum, but some replies, whilst specifying pain at least 252 
monthly or more often, did not specify whether the pain reached the threshold of three 253 
times per month; the duration of the IBS-like symptoms – some replies did not specify 254 
whether the pain had been experienced for at least 6 months, only that it was for several 255 
months. Cases who could not definitely be shown to meet the formal definition of Rome III 256 
for one of these reasons were categorised as ‘IBS-like’. 257 
A further 27% displayed all the Rome III criteria except that at 3 months post-infection they 258 
could not report >6months duration of symptoms. Thus in total 37% of cases fell into the 259 
categories IBSRIII or IBSRIII<6m. Another 23% had several features of IBS but lacked one 260 




Previous work has suggested that children rarely develop sequelae, in contrast to adults 263 
[25]. The findings of this study do not support this. The manifestations of IBS are different in 264 
paediatric practice, and this is reflected in differences in the Rome III criteria for different 265 
age groups. This study analysed the Rome III diagnostic criteria for each age group in detail 266 
and this is likely to account for differences compared to previous work. 267 
 268 
Overall, persistent gastrointestinal symptoms were noted in 59% of the cases during the 269 
study period and 10% of cases had features diagnostic for IBS at 12 months.  No significant 270 
difference was seen between C. parvum and C. hominis with regard to IBS. In a previous 271 
study of C. parvum outbreak cases [10], 28% had symptoms consistent with IBS over the 272 
course of 1 year follow-up and two of 54 patients received a medical diagnosis of IBS. 273 
Similarly, among patients who have suffered bacterial gastroenteritis, persistent bowel 274 
dysfunction has been recorded in around 25% [26]. Around 7% of patients were found to 275 
have developed IBS following bacterial gastroenteritis [27], a figure not dissimilar to that 276 
found in our study.   277 
A limitation of this study was that the number of respondents dropped off somewhat at 278 
each timepoint, as might be expected. Of the 205 cases who completed the baseline 279 
survery, ninety-six completed the 12 month survey.  280 
This study adds weight to the recent body of evidence that post-infectious gastrointestinal 281 
dysfunction after cryptosporidiosis is common, and patients should be given realistic 282 
expectations regarding recovery. Fatigue and abdominal pain were frequently reported up 283 
to 12 months after acute illness and was significantly more common after C. hominis 284 
infection compared to C. parvum infection. Around 10% of people had symptoms which 285 
merited a formal diagnosis of IBS following cryptosporidiosis.   286 
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